Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Enanta Pharmaceuticals, Inc. - Common Stock
(NQ:
ENTA
)
13.18
+0.27 (+2.09%)
Streaming Delayed Price
Updated: 12:20 PM EST, Jan 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enanta Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022
October 19, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus
October 17, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus
October 03, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Recap: Enanta Pharmaceuticals Q3 Earnings
↗
August 08, 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q3 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium
September 29, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
September 22, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022
September 07, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Enanta Pharmaceuticals
↗
July 01, 2022
Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings:
Via
Benzinga
Expert Ratings for Enanta Pharmaceuticals
↗
June 01, 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
September 01, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
August 08, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
August 08, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals
↗
August 01, 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022
August 01, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Recap Of Friday's Biotech Catalysts - End of The Day Summary
↗
July 29, 2022
Via
Benzinga
Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study
↗
July 29, 2022
Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple...
Via
Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
↗
July 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants
↗
July 29, 2022
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced topline data from a Phase 1 study of EDP-235 in healthy adult subjects. EDP-235, a coronavirus 3CL protease inhibitor, is designed to be a...
Via
Benzinga
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
July 29, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
↗
July 07, 2022
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022
↗
July 06, 2022
Upgrades
Via
Benzinga
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
↗
June 28, 2022
Via
Benzinga
Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid
↗
June 22, 2022
Another company says it invented the technology behind the pill first.
Via
Investor's Business Daily
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
↗
June 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer
June 21, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
June 08, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate in Two Investor Conferences in June
June 02, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022
↗
June 01, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
↗
May 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint
↗
May 18, 2022
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
